Raj Vuppalanchi, MD
Internal Medicine · Indianapolis, INNPI 1588872923
Payments from drug & device makers
Across 731 payments — averaging $4676.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$851K
- Eli Lilly$734K
- Novo Nordisk AS$361K
- Takeda Pharmaceuticals U.S.A., Inc.$308K
- Intercept Pharmaceuticals, Inc.$246K
- Intercept Pharma Europe Ltd.$246K
- plus $672K from 20 others
Across 17 payments — averaging $862.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Regeneron$2K
- Gilead$2K
- Eli Lilly$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 99 | $851,328 |
| Eli Lilly | 17 | $733,691 |
| Novo Nordisk AS | 329 | $361,058 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $308,470 |
| Intercept Pharmaceuticals, Inc. | 54 | $245,953 |
| Intercept Pharma Europe Ltd. | 9 | $245,745 |
| GSK | 56 | $241,618 |
| Astrazeneca UK Limited | 7 | $122,132 |
| La Jolla Pharmaceutical Company | 14 | $117,230 |
| Perspectum Diagnostics Ltd | 9 | $84,801 |
| Madrigal Pharmaceuticals | 11 | $23,250 |
| Jazz Pharmaceuticals Inc. | 32 | $20,375 |
| Daiichi Sankyo Inc. | 4 | $13,635 |
| Echosens North America, Inc. | 13 | $13,366 |
| Agios Pharmaceuticals, Inc. | 8 | $9,301 |
| Ipsen Biopharmaceuticals, Inc | 3 | $8,223 |
| Merck | 9 | $7,969 |
| Regeneron | 2 | $6,399 |
| Biomarin Pharmaceutical Inc. | 2 | $1,529 |
| Greenwich Biosciences, Inc. | 1 | $1,300 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $487 |
| Sequana Medical US Inc. | 1 | $222 |
| Novo Nordisk | 2 | $135 |
| Fujifilm Healthcare Americas Corporation | 2 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $30 |
| Johnson & Johnson | 1 | $28 |
How this compares
$3,418,404 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Indianapolis
- Phillip TothIndianapolis$3.2M
- Georgiann LinnemeierIndianapolis$692K
- Allon FriedmanIndianapolis$524K
- Eromonsele IdahosaIndianapolis$471K
- Misty ShieldsIndianapolis$411K
- Pei LuIndianapolis$298K
- Paul DexterIndianapolis$161K
- Jon DukeIndianapolis$138K
- Napoleon MamintaIndianapolis$116K
- John AyresIndianapolis$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.